Fera Pharmaceuticals Announces FDA Approval of Avaclyr™ (acyclovir ophthalmic ointment)
NEW YORK--(BUSINESS WIRE)--The US Food and Drug Administration (FDA) has approved Fera’s New Drug Application (NDA) for Avaclyr™ (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis. Orphan drug exclusivity was also granted, providing seven years of marketing exclusivity for the product. “Avaclyr approval is a major milestone for the company,” noted Frank DellaFera, Fera’s founder and President. “Working closely with the eye care community we were able to identify a need f